Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients

References

• Gomes AL, Teijeiro A, Burén S, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30(1):161–175.27411590
   PubMed Web of Science ®Google Scholar
• Huang CY, Wang Y, Luo GY, et al. Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma. J Immunother. 2017;40(9):323–333. doi:10.1097/CJI.000000000000018729028787
   PubMed Web of Science ®Google Scholar
• Barsoum IB, Smallwood CA, Siemens DR, et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74(3):665–674. doi:10.1158/0008-5472.CAN-13-099224336068
   PubMed Web of Science ®Google Scholar
• Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity. Front Immunol. 2014;5:543. doi:10.3389/fimmu.2014.0054325389427
   PubMed Web of Science ®Google Scholar
• Dugnani E, Pasquale V, Bordignon C, et al. Integrating T cell metabolism in cancer immunotherapy. Cancer Lett. 2017;411:12–18. doi:10.1016/j.canlet.2017.09.03928974448
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Borman ZA, Gattinoni L, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2011;117(3):808–814. doi:10.1182/blood-2010-05-28628620971955
   PubMed Web of Science ®Google Scholar
• Singh A, Schabath R, Ratei R, et al. Peripheral blood sCD3(-) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol Oncol. 2014;32(1):16–21. doi:10.1002/hon.v32.123798351
   PubMed Web of Science ®Google Scholar
• Awad MM, Jones RE, Liu H, et al. Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors. Cancer Immunol Res. 2016;4(12):1038–1048. doi:10.1158/2326-6066.CIR-16-017127856426
   PubMed Web of Science ®Google Scholar
• Zhu P, Hu C, Hui K, Jiang X. The role and significance of VEGFR2(+) regulatory T cells in tumor immunity. Onco Targets Ther. 2017;10:4315–4319. doi:10.2147/OTT.S14208528919780
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-tumor immunity. Int Immunol. 2015;27(10):521–530. doi:10.1093/intimm/dxv03425999597
   PubMed Web of Science ®Google Scholar
• Saavedra D, García B, Lorenzo-Luaces P, et al. Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients. Cancer Immunol Immunother. 2016;65(1):37–45. doi:10.1007/s00262-015-1773-626589409
   PubMed Web of Science ®Google Scholar
• Peng Y, Ma J, Yang X, et al. Peripheral CD4+ naive/memory ratio is an independent predictor of survival in non-small cell lung cancer. Oncotarget. 2017;8(48):83650–83659. doi:10.18632/oncotarget.1933029137371
   PubMedGoogle Scholar
• Lan YT, Fan X-P, Fan Y-C, et al. Change in the Treg/Th17 cell imbalance in hepatocellular carcinoma patients and its clinical value. Medicine (Baltimore). 2017;96(32):e7704. doi:10.1097/MD.000000000000770428796055
   PubMed Web of Science ®Google Scholar
• Chang Q, Hedley D. Emerging applications of flow cytometry in solid tumor biology. Methods. 2012;57(3):359–367. doi:10.1016/j.ymeth.2012.03.02722503773
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.02520303878
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–271. doi:10.1146/annurev-immunol-031210-10132421219185
   PubMed Web of Science ®Google Scholar
• Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(1):24–35. doi:10.1038/nri356724336101
   PubMed Web of Science ®Google Scholar
• Hishiki T, Mise N, Harada K, et al. Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors. Pediatr Surg Int. 2018;34(2):169–176. doi:10.1007/s00383-017-4185-129018953
   PubMed Web of Science ®Google Scholar
• Singh N, Shi J, June CH, Ruella M. Genome-editing technologies in adoptive T cell immunotherapy for cancer. Curr Hematol Malig Rep. 2017;12(6):522–529. doi:10.1007/s11899-017-0417-729039115
   PubMed Web of Science ®Google Scholar
• Erfani N, Mehrabadi SM, Ghayumi MA, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2012;77(2):306–311. doi:10.1016/j.lungcan.2012.04.01122608141
   PubMed Web of Science ®Google Scholar
• Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9(12):4404–4408.14555512
   PubMed Web of Science ®Google Scholar
• Diller ML, Kudchadkar RR, Delman KA, et al. Balancing inflammation: the link between Th17 and regulatory T cells. Mediators Inflamm. 2016;2016:6309219. doi:10.1155/2016/630921927413254
   PubMed Web of Science ®Google Scholar
• Liu C, Wu S, Meng X, et al. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy. Oncotarget. 2017;8(26):43427–43438. doi:10.18632/oncotarget.1523828624781
   PubMedGoogle Scholar
• Yang C, Lee H, Pal S, et al. B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS One. 2013;8(5):e64159. doi:10.1371/journal.pone.006415923734190
   PubMed Web of Science ®Google Scholar
• Sarvaria A, Madrigal JA, Saudemont A. B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol. 2017;14(8):662–674. doi:10.1038/cmi.2017.3528626234
   PubMed Web of Science ®Google Scholar
• DeFalco J, Harbell M, Manning-Bog A, et al. Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens. Clin Immunol. 2018;187:37–45. doi:10.1016/j.clim.2017.10.00229031828
   PubMed Web of Science ®Google Scholar
• Wang WW, Yuan XL, Chen H, et al. CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer. Oncotarget. 2015;6(32):33486–33499. doi:10.18632/oncotarget.558826378021
   PubMedGoogle Scholar
• Noh J, Noh G, Kim HS, et al. Allergen-specific responses of CD19(+)CD5(+)Foxp3(+) regulatory B cells (bregs) and CD4(+)Foxp3(+) regulatory T cell (tregs) in immune tolerance of cow milk allergy of late eczematous reactions. Cell Immunol. 2012;274(1–2):109–114. doi:10.1016/j.cellimm.2012.01.00522398308
   PubMed Web of Science ®Google Scholar
• Blair PA, Noreña LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010;32(1):129–140. doi:10.1016/j.immuni.2009.11.00920079667
   PubMed Web of Science ®Google Scholar
• Aybar LT, McGregor JG, Hogan SL, et al. Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies. Clin Exp Immunol. 2015;180(2):178–188. doi:10.1111/cei.1248325376552
   PubMed Web of Science ®Google Scholar
• Amand M, Iserentant G, Poli A, et al. Human CD56(dim)CD16(dim) cells as an individualized natural killer cell subset. Front Immunol. 2017;8:699. doi:10.3389/fimmu.2017.0069928674534
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J; Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432–1433. doi:10.1126/science.342.6165.143224357284
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415–2426. doi:10.1056/NEJMoa161349328636851
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob -J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855. doi:10.1056/NEJMoa161129927717298
   PubMed Web of Science ®Google Scholar
• Qin L, Jing X, Qiu Z, et al. Aging of immune system: immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults. Aging (Albany NY). 2016;8(5):848–859. doi:10.18632/aging.v8i526886066
   PubMedGoogle Scholar
• Henny J, Vassault A, Boursier G, et al. Recommendation for the review of biological reference intervals in medical laboratories. Clin Chem Lab Med. 2016;54(12):1893–1900. doi:10.1515/cclm-2016-079327748267
   PubMed Web of Science ®Google Scholar